Post-TAVR stroke is rare, but it can be fatal. A new study in Catheterization and Cardiovascular Interventions examined the issue in great detail, focusing on more than 2,700 patients treated over a two-year stretch. 

The investigation also used secure messaging, allowing clinicians to receive real-time alerts via their smartphones to notify them of a possible LVO minutes after the completion of a CT. 

The biggest differences between the two treatment options were major bleeding events and all-cause mortality. There was no significant difference when it came to stroke risk. 

The study’s authors examined data from more than 15,000 patients who had their first intracerebral hemorrhage from January 2003 to December 2021

El Segundo, California-based RP said the recommendations are derived from current guidelines and the “extensive expertise” of its neuroradiology division. 

A team of specialists tracked CT utilization before, during and after the 2022 shortage, sharing its findings in the American Journal of Neuroradiology.

The disparity appeared concentrated among white, privately insured, higher income, and middle aged (50-79 year-old) men. 

The FDA has categorized this as a Class I recall, which means using the devices “may cause serious injuries or death.”